ta-2005
Small moleculeexperimental
Clinical trial activity
5 trials · 6 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
4
Phase 3
0
Phase 4
0
Earliest trial started Oct 1, 2006 (NCT00605891)
Timeline
Indications
Mechanism of action
- Beta-2 adrenergic receptorAGONIST
ADRB2 agonist
Discontinued does not have competitive profile (http://www.chiesi.es/Assets/docs/Annual_report_2010.pdf)
Chemistry & pharmacology
Loading structure…
SMILES
COc1ccc(C[C@@H](C)NC[C@H](O)c2ccc(O)c3[nH]c(=O)ccc23)cc1- Mol. weight
- 368.43 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL1094785 ↗
Also known as
- 8-hydroxy-5-((1r)-1-hydroxy-2-(((2r)-2-(4- methoxyphenyl)propan-2-yl)amino)ethyl)quinolin-2(1h)-one
- carmoterol
- carmoterol
- carmoterol
- carmoterol
- carmoterol hydrochloride
- chf 4226
- chf 4226
- chf-4226
- chf-4226
- chf 4226.01
- chf4232.01
- ta 2005
- ta-2005
- ta-2005
- ta-2005
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT01070524 | Phase 2 | Jan 1, 2010 | Chiesi, Medicines Evaluation Unit Ltd |
| NCT00782535 | Phase 2 | Dec 1, 2008 | Chiesi, New Horizons Clinical Research |
| NCT00777595 | Phase 1 | Oct 1, 2008 | Chiesi, PRACS |
| NCT00640484 | Phase 2 | Apr 1, 2008 | Chiesi, University of California, Los Angeles |
| NCT00605891 | Phase 2 | Oct 1, 2006 | Chiesi, University of Colorado, Denver |
Showing 5 of 5 trials
Page 1 / 1
Organizations
Research & Development (6)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Chiesi | For profit | 5 | 5 | 2 | 2006 |
| Medicines Evaluation Unit Ltd | For profit | 1 | 0 | 1 | 2010 |
| New Horizons Clinical Research | For profit | 1 | 0 | 1 | 2008 |
| PRACS | For profit | 1 | 0 | 1 | 2008 |
| University of California, Los Angeles | Academic/Hospital | 1 | 0 | 1 | 2008 |
| University of Colorado, Denver | Academic/Hospital | 1 | 0 | 1 | 2006 |
6 organizations
Page 1 / 1